期刊文献+

浅析国际药品不良反应监测数据发布和反馈 被引量:4

下载PDF
导出
摘要 目的:了解国际药品不良反应监测数据反馈和公开的政策和做法,为我国开展相关工作提供借鉴和参考。方法:调研美国、欧盟、世界卫生组织药品不良反应监测数据发布和反馈的内容和途径。结果:美国、欧盟、世界卫生组织建立了针对不同性质的药品不良反应信息通过不同的渠道和方式进行发布和反馈的机制。结论:吸收借鉴国际经验,结合我国的药品安全监管特点,加强药品不良反应监测信息发布和反馈。
出处 《药物流行病学杂志》 CAS 2013年第9期516-519,共4页 Chinese Journal of Pharmacoepidemiology
  • 相关文献

参考文献8

二级参考文献31

  • 1European Commission. The EU pharmacovigilance system[EB/OL]. http://ec.europaeu/health/human-use/pharmacovigilance/index_en. htm#geninf( 2012-09-16 ).
  • 2Peter Arlett. New Pharmacovigilance legislation and focus on post-authorisation studies (2010-11-29)[EB/OL].www.diahome. org/.../24003/session%203_peter%20arlett.pdf (2012-9-16).
  • 3European Medicines Agency. 2010 pharmacovigilance legislation [EB/OL].http://www.ema.europa.eu/ema/index.j sp curl=pages/ regulation/general/general_content_000492.j sp&mid=WC0b01 ac 058033e8ad (2012-9-16).
  • 4European Medicines Agency. Commission Implementing Regula- tion (EU) No 520/2012 (2012-6-19)[EB/OL]. http://eurx.europa. eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025: EN:PDF (2012-9-16).
  • 5European Medicines Agency. Good Pharmacovigilance Practices [ EB/OL ]. http://www, ema. europa, eu/ema/index .j sp curl=pages/ regulation/document_listing/document_listing_000345. j sp&mid=WC0b01 ac058058f32c ( 2012-9-16 ).
  • 6European Medicines Agency. GVP Module I Pharmacovigilance Systems and their Quality Systems (2012-6-22) [EB/OL].http:// www.ema.europa.eu/docs/en_GB/document_library/Scientif- ic_guideline/2012/06/WC500129132.pdf( 2012-09-17 ).
  • 7European Medicines Agency. GVP Module II Pharmacovigilance System Master File(2012-6-22 ) [EB/OL].http://www.ema.europa. eu/docs/en GB/document_library/Scientific_guideline/2012/06/ WCS00129133.pdf(2012-09-17).
  • 8European Medicines Agency. GVP Module III Pharmacovigilance Inspections( 2012-6-22 ) [EB/OL] .http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2012/06/WC500129243. pdf(2012-09-17).
  • 9European Medicines Agency. GVP Module V- Risk Management Systems( 2012-6-22 )[EB/OL].http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2012/06/WC500129134. pdf(2012-9-18).
  • 10European Medicines Agency. GVP Module VI - Management and Reporting of Adverse Reactions to Medicinal Products( 2012-06- 22) [EB/OL].http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2012/06/WC500129135.pdf( 2012- 09-18).

共引文献45

同被引文献36

  • 1国家食品药品监督管理总局.国家食品药品监督管理局安监司关于征求《关于推动生产企业开展药品重点监测工作的通知(征求意见稿)》意见的函[EB/OL].http://www.sfda.gov.cn/WS01/CL0778/79321.html,2013-03-25/2013-11-30.
  • 2Wu XT, Hu FY, An DM,et al. Association between carbamaz- epine-induced cutaneous adverse drug reactions and the HLA-B 1502 allele among patients in central China[J]. Epilepsy Be- hay,2010,19(3) :405-408.
  • 3Sakaeda T,Kadoyama K,Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system[J ]. Plos One, 2011,6 (12):e 28124.
  • 4Wang XQ, Lang SY, Shi XB, et al. Antiepileptic drug-induced skin reactions:a retrospective study and analysis in 3793 Chi- nese patients with epilepsy[J]. Clin Neurol Neurosurg, 2012, 114(7) : 862-865.
  • 5Hu FY,Wu XT,An DM,etal. Pilot association study of oxcar-bazepine-induced mild cutaneous adverse reactions with HLA- B 1502 allele in Chinese Han population[J]. Seizure,2011,20 (2) : 160-162.
  • 6Lv YD, Min FL, Liao W P, et al. The association between ox- carbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population[J]. BMC Neurol, 21113, 13:75.
  • 7武志昂,毕开顺.药品风险管理之风险的起因分析——关于药品天然风险[J].中国处方药,2008(1):49-51. 被引量:11
  • 8Karen M.药品监测与安全信号发掘[J].中国药物警戒,2009,6(3):191-192. 被引量:5
  • 9李莉霞,陆晓彤,刘海涛,刘艳,唐跃年,李永洋,张健.影响医务人员上报儿童药物不良反应的相关因素调查[J].中国临床药学杂志,2010,19(4):212-216. 被引量:8
  • 10何学莲,王芳琳,吴革菲,孙丹,康世秀,胡家胜,毛冰,何彩英,刘智胜.奥卡西平诱发的Stevens-Johnson综合征的临床特点及基因表达[J].实用儿科临床杂志,2011,26(5):360-362. 被引量:17

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部